# Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.

> **NCT07107529** · PHASE2 · RECRUITING · sponsor: **European Myeloma Network B.V.** · enrollment: 150 (estimated)

## Conditions studied

- Multiple Myeloma (MM)

## Interventions

- **DRUG:** Teclistamab
- **DRUG:** Talquetamab
- **DRUG:** Daratumumab

## Key facts

- **NCT ID:** NCT07107529
- **Lead sponsor:** European Myeloma Network B.V.
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-12
- **Primary completion:** 2029-04
- **Final completion:** 2034-02
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-04-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07107529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07107529, "Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07107529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*